TREAT THE
TRINITY
for people with uncontrolled type 2 diabetes
A GAME CHANGER. A LIFE CHANGER.
with
Unprecedented
HbA1c reduction
HbA1c reduction
Up to 1.5%
reduction in HbA1c*7
reduction in HbA1c*7
Unsurpassed
weight loss
weight loss
~20% achieved
>10% weight loss8
>10% weight loss8
Synergistic benefits of Rybelsus®>>>
Not a real patient. The images of person depicted are for illustration purposes only.
Not a real case profile, depicted profile is for hypothetical purposes only
*Baseline HbA1c of 8.0%,
Abbreviations: T2DM: Type 2 diabetes Mellitus, HbA1c: Glycated hemoglobin,
Not a real case profile, depicted profile is for hypothetical purposes only
*Baseline HbA1c of 8.0%,
Abbreviations: T2DM: Type 2 diabetes Mellitus, HbA1c: Glycated hemoglobin,
TREAT THE
TRINITY
for people with uncontrolled type 2 diabetes
A GAME CHANGER. A LIFE CHANGER.
with
Target Residual CVD Risk with Dual Therapy:
Benefits of adding Oral semaglutide as combination with SGLT2is9
Benefits of adding Oral semaglutide as combination with SGLT2is9
-1.1%
Additional
HbA1c reduction*9
HbA1c reduction*9
-5.0 kg
Additional
weight loss*9
weight loss*9
when added to metformin + SGLT2i*9
*Results are from a post-hoc analysis of PIONEER 4, a 52-week, double-blind, double-dummy trial in 711 adult patients with type 2 diabetes. Patients who entered the trial were
either on metformin alone or metformin plus an SGLT-21. All patients were randomised to RYBELSUS 14 mg, liraglutide 1.8 mg, or placebo in PIONEER 4. Over the course of the
thal, those patients who continued on a stable regimen with metformin plus an SGLT-21 demonstrated a slight increase (0.4%) in HOA, compared to a-1.1% reduction
either on metformin alone or metformin plus an SGLT-21. All patients were randomised to RYBELSUS 14 mg, liraglutide 1.8 mg, or placebo in PIONEER 4. Over the course of the
thal, those patients who continued on a stable regimen with metformin plus an SGLT-21 demonstrated a slight increase (0.4%) in HOA, compared to a-1.1% reduction
